COM Entering Class of 2017

Search results

• Reports on Health and Medicine from Oklahoma State University Provide New Insights (Reporting of Patient-reported Outcomes In Trials On Alcohol Use Disorder: a Meta-epidemiological Study)

  Vassar, M., Hartwell, M., Ottwell, R., Shepard, S., Hillman, C. & Wise, A.

  24/01/24

  1 item of Media coverage

  Press/Media

• Research Findings from Oklahoma State University Center for Health Sciences Update Understanding of Inflammatory Bowel Disease (Evaluating Reporting of Patient-Reported Outcomes in Randomized Controlled Trials Regarding Inflammatory Bowel ...)

  Vassar, M., Hartwell, M., Ottwell, R., Wise, A., Kee, M., Hillman, C. & Anderson, R.

  7/12/23

  1 item of Media coverage

  Press/Media

• FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

  Roberts, W.

  23/08/23

  1 item of Media coverage

  Press/Media

• Study Data from Oklahoma State University Update Knowledge of Psoriasis (An Evaluation of Spin In the Abstracts of Systematic Reviews and Meta-analyses On the Treatment of Psoriasis: a Cross-sectional Analysis)

  Vassar, M., Arthur, W., Cook, C., Miao, Z., Hartwell, M., Ottwell, R. & Hillman, C.

  10/08/23

  1 item of Media coverage

  Press/Media

• Oklahoma State University Center for Health Sciences Reports Findings in Strabismus (Evaluation of Quality of Systematic Reviews and Meta-Analyses Abstracts for Pediatric Strabismus Therapies)

  Vassar, M., Hartwell, M., Demla, S. & Khattab, M.

  27/07/23

  1 item of Media coverage

  Press/Media

• Students benefitting from SE’s partnership with OSU College of Osteopathic Medicine

  Sharp, P.

  8/06/23

  1 item of Media coverage

  Press/Media

• Findings from Oklahoma State University Provide New Insights into Traumatic Stress Disorders (Assessment of Reporting of Patient-reported Outcomes In Randomized Controlled Trials for Interventions of Post-traumatic Stress Disorder)

  Hartwell, M., Vassar, M., Ottwell, R., Anderson, R., Shepard, S., Hillman, C. & Wise, A.

  27/04/23

  1 item of Media coverage

  Press/Media

• Researcher at Oklahoma State University Center for Health Sciences Has Published New Study Findings on Sports Medicine (Assessment of Spin in the Abstracts of Systematic Reviews and Meta-analyses on Platelet-Rich Plasma Treatment in ...)

  Ottwell, R., Reddy, A., Wirtz, A., Vassar, M., Hartwell, M., Lulkovich, K. & Hanson, C.

  7/03/23

  1 item of Media coverage

  Press/Media

• Reports from Oklahoma State University Advance Knowledge in Clinical Trial Research (The Evaluation of Reporting of Patient-reported Outcomes In Mdd: a Meta-epidemiological Study of Clinical Trials)

  Hartwell, M., Vassar, M., Ottwell, R., Shepard, S., Hillman, C., Wise, A. & Kee, M.

  2/02/23

  1 item of Media coverage

  Press/Media

• Studies from Oklahoma State University Further Understanding of Skin Cancer (Lifestyle Behaviors and Sun Exposure Among Individuals Diagnosed With Skin Cancer: a Cross-sectional Analysis of 2018 Brfss Data)

  Hartwell, M. & Ottwell, R.

  10/11/22

  1 item of Media coverage

  Press/Media

• New Hyponatremia Research Has Been Reported by Researchers at Department of Medicine (Severe hyponatremia due to trimethoprim-sulfamethoxazole-induced SIADH)

  Bannon, M., Kaushik, P., Ashraf, A. & Nunley, M. O.

  7/11/22

  1 item of Media coverage

  Press/Media

• NC doctor: Abortion saves lives. It saved my grandmother’s in the 1970s

  Arthur, W.

  20/09/22

  1 item of Media coverage

  Press/Media

• UAMS NAMES NEW INTERNAL MEDICINE, FAMILY MEDICINE RESIDENT PHYSICIANS IN NORTHWEST ARKANSAS

  Arthur, W.

  2/08/21

  1 item of Media coverage

  Press/Media

• UAMS Names New Internal Medicine, Family Medicine Resident Physicians in Northwest Arkansas

  Arthur, W.

  2/08/21

  1 item of Media coverage

  Press/Media

• FDA APPROVES G1 THERAPEUTICS’ COSELA™ (TRILACICLIB): THE FIRST AND ONLY MYELOPROTECTION THERAPY TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION

  Roberts, W.

  18/02/21

  1 item of Media coverage

  Press/Media

• FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

  Roberts, W.

  15/02/21

  2 items of Media coverage

  Press/Media

• FDA Approves G1 Therapeutics’ COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

  Roberts, W.

  14/02/21

  1 item of Media coverage

  Press/Media

• FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

  Roberts, W.

  12/02/21 → 13/02/21

  29 items of Media coverage

  Press/Media

• Speaker Conflicts of Interest May Bias Testimony About Drugs

  Roberts, W.

  6/02/20

  2 items of Media coverage

  Press/Media

• Public speakers often mistaken about efficacy of drugs due to conflicts of interest

  Roberts, W.

  5/02/20

  1 item of Media coverage

  Press/Media

• Public opinion of drugs effectiveness may be too biased

  Roberts, W.

  4/02/20

  2 items of Media coverage

  Press/Media